1.40
+0.04(+2.94%)
Currency In USD
| Previous Close | 1.36 |
| Open | 1.37 |
| Day High | 1.42 |
| Day Low | 1.36 |
| 52-Week High | 3.78 |
| 52-Week Low | 0.86 |
| Volume | 1.05M |
| Average Volume | 2.71M |
| Market Cap | 314.62M |
| PE | -1.43 |
| EPS | -0.98 |
| Moving Average 50 Days | 1.31 |
| Moving Average 200 Days | 1.31 |
| Change | 0.04 |
If you invested $1000 in Allogene Therapeutics, Inc. (ALLO) since IPO date, it would be worth $56 as of December 25, 2025 at a share price of $1.4. Whereas If you bought $1000 worth of Allogene Therapeutics, Inc. (ALLO) shares 5 years ago, it would be worth $51.81 as of December 25, 2025 at a share price of $1.4.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
GlobeNewswire Inc.
Dec 15, 2025 10:39 PM GMT
Arbitration Ruling Reaffirms Allogene’s Full Control of Cemacabtagene Ansegedleucel (Cema-Cel)Decision Reconfirms Allogene’s Expanded Sub-License Covering EU and UK Rights with Options for Japan and China, Clearing the Path for Allogene to Acquire Fu
Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update
GlobeNewswire Inc.
Nov 06, 2025 9:05 PM GMT
Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 Positions Company at the Forefront of MRD-guided, Earlier-Line Oncology TreatmentAdditional Sites in Aust
Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting
GlobeNewswire Inc.
Nov 03, 2025 2:04 PM GMT
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease